Neuroscience
The endocannabinoid system — from receptors to cognition
The endocannabinoid system (ECS) is one of the most widespread neuromodulatory systems in the brain, regulating synaptic plasticity, neuroinflammation, mood, memory, and pain. Understanding its pharmacology is foundational to interpreting all cannabinoid research.
What the Research Shows
The endocannabinoid system comprises two primary receptors (CB1 and CB2), endogenous ligands (anandamide and 2-AG), and degradative enzymes (FAAH and MAGL). CB1 receptors are among the most abundant GPCRs in the brain, concentrated in the basal ganglia, hippocampus, cerebellum, and prefrontal cortex — explaining cannabis's effects on movement, memory, coordination, and executive function. CB2 receptors are expressed primarily in immune cells and microglia, with emerging evidence for neuronal CB2 expression in the brainstem and striatum. Exogenous cannabinoids (THC, CBD) interact with this system in complex ways: THC is a partial CB1/CB2 agonist producing psychoactive effects; CBD is a negative allosteric modulator of CB1 and has multiple non-cannabinoid receptor targets. Adolescent exposure to THC during critical periods of neurodevelopment is associated with lasting changes in CB1 receptor density and cognitive function. Conversely, the ECS is a promising therapeutic target for neuroinflammatory and neurodegenerative conditions.
Key Findings
CB1 receptors are among the most abundant GPCRs in the brain
Well-StudiedDense expression in hippocampus, prefrontal cortex, basal ganglia, and cerebellum explains cannabis's cognitive and motor effects.
Adolescent THC exposure alters CB1 receptor density
Well-StudiedAnimal and human neuroimaging studies show lasting CB1 downregulation following adolescent cannabis exposure.
THC causes 20% CB1 downregulation after 4 weeks
Emerging ResearchPET imaging study found significant receptor downregulation correlating with tolerance, partially reversible after abstinence.
CB2 agonism reduces neuroinflammation
Emerging ResearchPreclinical models show CB2 activation reduces microglial activation and pro-inflammatory cytokines without psychoactive effects.
Featured Studies
View all in libraryCommon Questions
What We Still Don't Know
These are open research questions — areas where the evidence is insufficient or actively contested.
- 1Do cannabinoids have disease-modifying effects in neurodegenerative diseases?
- 2What is the full extent of neuronal CB2 receptor expression and function?
- 3Can FAAH or MAGL inhibitors (endocannabinoid-enhancing drugs) treat neurological conditions?
- 4How does the ECS interact with the serotonin and dopamine systems?
- 5What are the long-term neurological consequences of daily cannabis use in adults?